As the costs and resourcing challenges of hospital-based cancer care continue to grow, Dr Toby Basey-Fisher, CEO & founder of Entia, explains why implementing robust home-based patient support programmes is a win-win for pharmaceutical companies.
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc.
Mike Hook, Sales & Marketing Director for PRAB, explores how wastewater recycling is a pathway to lower risk exposure and water costs in pharmaceutical manufacturing.
Alan Messenger, Sales Director at Optimal Industrial Automation, and Manuel Kuhs, Business Development Manager for Europe at Optimal Industrial Technologies, look at the importance of PAT software for Pharma 4.0-oriented data management.
The UK pharmaceutical sector is forecast to grow faster than its European peers but prevailing productivity issues could scupper progress, research from business insurer QBE has found.
Dr Robin Knight, Co-Founder & Co-CEO of IN-PART, discusses the emerging importance of outsourcing landscaping activities within the pharmaceuticals industry and the benefits of adopting an openly innovative approach that pools sources of innovation.
